Please ensure Javascript is enabled for purposes of website accessibility

Why Chiasma’s Shares Are Down Today

By Prosper Junior Bakiny – Jul 1, 2020 at 11:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced the pricing of a public offering of common stock.

What happened?

On Wednesday morning, Chiasma, Inc. (CHMA) announced the pricing of a public offering of common stock and pre-funded warrants. Naturally, investors are not thrilled about the company's decision to dilute its existing shareholders, which explains why Chiasma's shares are plunging today. The company's stock is down by 10.4% as of 11:30 a.m. EDT today. 

So what

Chiasma first announced its intention to initiate a public offering of common stock and pre-funded warrants after the market closed on Tuesday. Today, the company said it intends to offer 12.5 million shares of its common stock for $4 per share, and the company will also sell pre-funded warrants to some investors -- which give said investors the right to purchase shares of its common stock at a later date -- for $3.99 per underlying share.

Man standing on a falling arrow, pulling a rope in an attempt to lift up the arrow.

Image source: Getty Images.

Chiasma is also giving underwriters a 30-day option to purchase an additional 2.625 million shares at the public offering price of $4 per share. Note that the company's shares closed at $5.38 apiece during the previous trading session. At writing, the company's shares are worth $4.66 apiece. Chiasma expects the gross proceeds from this public offering of common stock -- which will likely close on July 6 -- to be $70 million.

Now what

Chiasma's decision to raise money through a public offering of common stock is hardly surprising. The company had $79.3 million in cash and cash equivalents as of March 31, but during the first quarter, Chiasma did not report any revenue as it did not have any approved products on the market then. The company also recorded operating expenses of $15.7 million and a net loss of $15.4 million during the first quarter. Since this quarter ended, however, The U.S. Food and Drug Administration approved Chiasma's Mycapssa, a medicine used to treat a hormonal disorder called acromegaly. The healthcare company will use the proceeds from its public offering of common stock to support the launch of Mycapssa on the market. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.